| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acute generalized exanthematous pustulosis induced by atezolizumab in a patient with lung adenocarcinoma
|
Chang, Hua-Ching
|
|
|
159 |
C |
p. 175-176
|
artikel
|
| 2 |
An invisible group of COVID-19 victims; impact on Dutch lung cancer care
|
van Breeschoten, Jesper
|
|
|
159 |
C |
p. 177-178
|
artikel
|
| 3 |
Anti–cytotoxic T-lymphocyte–associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer
|
Cho, Byoung Chul
|
|
|
159 |
C |
p. 162-170
|
artikel
|
| 4 |
A retrospective observational study of the natural history of advanced non–small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease
|
Spira, Alexander I.
|
|
|
159 |
C |
p. 1-9
|
artikel
|
| 5 |
Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions
|
Mondaca, Sebastian
|
|
|
159 |
C |
p. 66-73
|
artikel
|
| 6 |
Clinicopathological, gene expression and genetic features of stage I lung adenocarcinoma with necrosis
|
Oiwa, Hiroaki
|
|
|
159 |
C |
p. 74-83
|
artikel
|
| 7 |
Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure
|
Lam, T.C.
|
|
|
159 |
C |
p. 18-26
|
artikel
|
| 8 |
Comment on: Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis
|
Wang, Le-Le
|
|
|
159 |
C |
p. 179-180
|
artikel
|
| 9 |
Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma
|
Kim, Roger Y.
|
|
|
159 |
C |
p. 107-110
|
artikel
|
| 10 |
Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors
|
Yoh, Kiyotaka
|
|
|
159 |
C |
p. 128-134
|
artikel
|
| 11 |
Considerable interlaboratory variation in PD-L1 positivity in a nationwide cohort of non-small cell lung cancer patients
|
Koomen, Bregje M.
|
|
|
159 |
C |
p. 117-126
|
artikel
|
| 12 |
Contents
|
|
|
|
159 |
C |
p. v-vi
|
artikel
|
| 13 |
Deregulated glutamate to pro-collagen conversion is associated with adverse outcome in lung cancer and may be targeted by renin-angiotensin-aldosterone system (RAS) inhibition
|
Kocher, Florian
|
|
|
159 |
C |
p. 84-95
|
artikel
|
| 14 |
DNA and RNA sequencing revealed a complex intergenic-ALK fusion in a lung adenocarcinoma patient who responded to TKI therapy
|
Zhang, Jiexia
|
|
|
159 |
C |
p. 171-174
|
artikel
|
| 15 |
Editorial Board
|
|
|
|
159 |
C |
p. iii
|
artikel
|
| 16 |
Health and economic impact at a population level of both primary and secondary preventive lung cancer interventions: A model-based cost-effectiveness analysis
|
Diaz, Mireia
|
|
|
159 |
C |
p. 153-161
|
artikel
|
| 17 |
Immune checkpoint inhibitors at any treatment line in advanced NSCLC: Real-world overall survival in a large Italian cohort
|
Andreano, Anita
|
|
|
159 |
C |
p. 145-152
|
artikel
|
| 18 |
KEAP1/NRF2 (NFE2L2) mutations in NSCLC – Fuel for a superresistant phenotype?
|
Dempke, Wolfram C.M.
|
|
|
159 |
C |
p. 10-17
|
artikel
|
| 19 |
Letter to the Editor: Comment on ‘Malignant pleural mesothelioma: Comparison of surgery-based trimodality therapy to medical therapy at two tertiary academic institutions’
|
Maat, Alexander P.W.M.
|
|
|
159 |
C |
p. 127
|
artikel
|
| 20 |
Prognosis of lung cancer associated with cystic airspaces: A propensity score matching analysis
|
Shen, Yingran
|
|
|
159 |
C |
p. 111-116
|
artikel
|
| 21 |
Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy
|
Seban, Romain-David
|
|
|
159 |
C |
p. 45-55
|
artikel
|
| 22 |
Proposal for Rib invasion as an independent T descriptor for non-small cell lung cancer: A propensity-score matching analysis
|
Zhao, Mengmeng
|
|
|
159 |
C |
p. 27-33
|
artikel
|
| 23 |
Pulmonary anatomy, pathology and treatment: What will be the artificial intelligence and deep-learning role on them?
|
Rossi, Umberto G.
|
|
|
159 |
C |
p. 181-182
|
artikel
|
| 24 |
Real-world insights into patients with advanced NSCLC and MET alterations
|
Bittoni, Marisa
|
|
|
159 |
C |
p. 96-106
|
artikel
|
| 25 |
The Pandora’s box of novel technologies that may revolutionize lung cancer
|
Rad, Habib Sadeghi
|
|
|
159 |
C |
p. 34-41
|
artikel
|
| 26 |
Tumor response to EGFR/BRAF/MEK co-inhibition in a patient with EGFR mutated lung adenocarcinoma developing a BRAFV600 mutation as an acquired resistance mechanism
|
Mauclet, Charlotte
|
|
|
159 |
C |
p. 42-44
|
artikel
|
| 27 |
UniPortal thoracoscopic pneumonectomy does not compromise perioperative and long-term survival in patients with NSCLC: A retrospective, multicenter, and propensity score matching study
|
Gao, Jiani
|
|
|
159 |
C |
p. 135-144
|
artikel
|
| 28 |
Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer
|
Kozono, David E.
|
|
|
159 |
C |
p. 56-65
|
artikel
|
Tijdschrift beschrijving